Biosimilars 301: Biosimilars in Canada Today – Payer, Policy, Patients and the Pharmacist Role

This course reviews the current landscape of biologics and biosimilars in Canada, as well as Health Canada’s guidance on the use of biosimilars in practice.

$0.00

Description

Description:

This course reviews the current landscape of biologics and biosimilars in Canada, as well as Health Canada’s guidance on the use of biosimilars in practice.
Pharmacists will learn about clinical considerations for the use of biosimilars through practical scenarios, as well as recommendations for minimizing the nocebo effect and for monitoring outcomes in patients using biologics.

Payer policy and its impact on patient care is discussed.  Pharmacists will develop greater confidence in helping to manage patients who are prescribed biologics and will learn how to embrace opportunities to collaborate with prescribers to meet patient needs.

Note: this course is developed/conceived by Pear Healthcare Solutions/Health eLearning.

Course outline:

  • Module 1:
    Biosimilars 301: Biosimilars in Canada Today
  • Module 2:
    Biosimilars 301 CE Test
  • Module 3:
    Course Evaluation: Biosimilars 301: Biosimilars in Canada Today

Sponsor(s)

This course has been supported by an educational grant from Amgen Canada.

Course at a glance:

  • 1 Hour to complete
  • 1 CEU
  • Available until April 23, 2022
  • Online
  • Accreditation: 1057-2019-2877-I-P
  • Completion requirement: After reviewing the course content, pass the CE Test with a score of 70% or higher to earn the CCCEP credit. You have two attempts to pass the CE Test.
  • Closed Captioning is available for this course.

Who should take this course:

Pharmacists

Development Team:

  • Subject Matter Expert:  Bev Herczegh, RPh, BScPhm
  • Reviewer: Chris Dalseg, RPh

Disclosures: The subject matter expert wishes to disclose that she was a paid speaker for Amgen as well as for a commercial entity other than this one. The reviewer has no conflicts of interest to disclose.